Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of “Hold” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus rating of “Hold” by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $40.8889.

A number of research firms have recently weighed in on AGIO. HC Wainwright cut their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Bank of America cut their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, May 29th. Truist Financial cut their price target on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Finally, The Goldman Sachs Group raised their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 1st.

Insider Transactions at Agios Pharmaceuticals

In other news, insider James William Burns sold 3,280 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,848.80. Following the completion of the sale, the insider directly owned 49,306 shares of the company’s stock, valued at $1,711,411.26. This trade represents a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Tsveta Milanova sold 3,262 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the transaction, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. The trade was a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 12,623 shares of company stock valued at $438,144 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AGIO. AQR Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after acquiring an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after acquiring an additional 2,920 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at approximately $40,000. Goldman Sachs Group Inc. raised its stake in shares of Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP bought a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at approximately $597,000.

Agios Pharmaceuticals Trading Up 3.3%

Shares of NASDAQ AGIO opened at $34.16 on Friday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The firm has a market capitalization of $2.03 billion, a PE ratio of -4.71 and a beta of 0.59. The business has a 50-day moving average price of $29.15 and a two-hundred day moving average price of $28.61.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals’s revenue for the quarter was up 137.7% compared to the same quarter last year. Research analysts anticipate that Agios Pharmaceuticals will post -6.28 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.